Abstract:Abstract Abstract #4068 Background: Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily and are known to be involved in the development of bone metastasis from solid tumours. Recent studies have shown that BMP-10 plays some critical roles during the fetal or postnatal development, particularly during the morphogenesis of heart. However, its role in cancer is largely unknown. The present study investigated the role of BMP-10 in breast cancer cells and pattern of expression in clinical breast cancers. Methods: The expression of BMP-10 was examined in a cohort of human breast cancer specimen (normal, n=23; cancer, n=97), using both quantitative real time PCR and immunohistochemical staining. Levels of BMP-10 transcripts were correlated with clinical and pathological, together with clinical outcome information of the patients. A human BMP-10 expression construct was used to transfect breast cancer cells (MDA-MB-231, negative in BMP-10 expression). The expression of BMP-10 in the transfected cells was verified using RT-PCR and western blot. The effect of BMP-10 expression on growth of MDA-MB-231 cells was investigated using an in vitro growth assay. Results: Immunohistochemical staining revealed a decreased protein expression of BMP-10 in breast cancer cells, compared with normal mammary epithelial cells. The quantitative real time PCR further demonstrated that low levels of the BMP-10 transcripts correlated to poor prognosis. Tumours form patients with good prognostic index (NPI<3.4) had significantly higher levels of BMP-10 transcripts, compared with those from poor prognostic index (NPI>5.4) (p=0.045). In addition, patients who died of breast cancer showed a significantly lower levels of the transcript compared with those who remained disease free (p=0.027). Mean disease free survival of the patients with higher level of BMP-10 was 132.8 (122.0-143.5, 95% CI) months, which was significantly longer compared to 93.7 (60.3-127.2) months of patients with lower level of BMP-10 expression, p=0.043 using Kaplan-Meirer survival analysis. An inhibitory effect on cell growth by over-expression of BMP-10 was seen in the breast cancer cells. The absorbance of MDA-MB-231 BMP-10 over-expressing (MDA-MB-231BMP-10exp) cells of Day 5 is 1.40±0.19, p<0.01 vs both MDA-MB-231 wild type (MDA-MB-231WT, 2.17±0.11) and empty vector control (MDA-MB-231pEF/His, 1.83±0.17). Conclusions: Taken together, BMP-10 can inhibit the cell growth of breast cancer cells. A decrease in BMP-10 expression correlates with poor prognosis of patients with breast cancer. BMP-10 may function as tumor suppressor in breast cancer. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4068.

Bone Morphogenetic Protein-10 Suppresses the Growth and Aggressiveness of Prostate Cancer Cells Through a Smad Independent Pathway.

Bone Morphogenetic Protein-9 Induces Apoptosis in Prostate Cancer Cells, the Role of Prostate Apoptosis Response-4

Bone Morphogenetic Protein 10 (Bmp-10) Inhibits Growth of Breast Cancer Cells and Correlates with Poor Prognosis

Bone Morphogenetic Protein 9 Overexpression Reduces Osteosarcoma Cell Migration and Invasion

Biological Roles of Human Bone Morphogenetic Protein 9 in the Bone Microenvironment of Human Breast Cancer MDA-MB-231 Cells.

BMP9 Regulates Cross-Talk Between Breast Cancer Cells and Bone Marrow-Derived Mesenchymal Stem Cells.

BMP9 Inhibits Proliferation and Metastasis of HER2-positive SK-BR-3 Breast Cancer Cells Through ERK1/2 and PI3K/AKT Pathways.

Expression of Bone Morphogenetic Protein-10 (BMP10) in Human Urothelial Cancer of the Bladder and Its Effects on the Aggressiveness of Bladder Cancer Cells in Vitro.

Bone Morphogenetic Protein 9 Regulates the Cross-Talk Between Breast Cancer Cells and Bone Marrow Mesenchymal Stem Cells

Effects of human bone morphogenetic protein 9 on migration and apoptosis of human breast cancer cells in simulated bone microenvironment in vitro

Bone Morphogenetic Protein-6 Promotes Osteoblastic Prostate Cancer Bone Metastases Through A Dual Mechanism

Bone Morphogenetic Proteins and Their Receptor Signaling in Prostate Cancer.

Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease

Endogenous Bone Morphogenetic Protein-7 Controls the Motility of Prostate Cancer Cells Through Regulation of Bone Morphogenetic Protein Antagonists

Opposing Roles of TGFβ and BMP Signaling in Prostate Cancer Development

Repulsive Guidance Molecules, Novel Bone Morphogenetic Protein Co-Receptors, Are Key Regulators of the Growth and Aggressiveness of Prostate Cancer Cells

Hepatocyte Growth Factor Up-Regulates the Expression of the Bone Morphogenetic Protein (BMP) Receptors, BMPR-IB and BMPR-II, in Human Prostate Cancer Cells.

Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial–mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathway

HOXD13 Suppresses Prostate Cancer Metastasis and BMP4‐induced Epithelial‐mesenchymal Transition by Inhibiting SMAD1

Bone morphogenetic protein 1: a prognostic indicator and potential biomarker in three cancer types

Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4